These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22270220)

  • 1. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma.
    Ellingson BM; Cloughesy TF; Zaw T; Lai A; Nghiemphu PL; Harris R; Lalezari S; Wagle N; Naeini KM; Carrillo J; Liau LM; Pope WB
    Neuro Oncol; 2012 Mar; 14(3):333-43. PubMed ID: 22270220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Liau LM; Pope WB
    Neuro Oncol; 2013 Mar; 15(3):382-90. PubMed ID: 23275575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
    Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
    AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.
    Chakhoyan A; Woodworth DC; Harris RJ; Lai A; Nghiemphu PL; Liau LM; Pope WB; Cloughesy TF; Ellingson BM
    J Neurooncol; 2018 Sep; 139(3):651-659. PubMed ID: 29855771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of combined visualization of MR diffusion and perfusion maps in glioblastoma.
    Deike K; Wiestler B; Graf M; Reimer C; Floca RO; Bäumer P; Kickingereder P; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    J Neurooncol; 2016 Feb; 126(3):463-72. PubMed ID: 26518541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
    Magn Reson Med; 2012 Jan; 67(1):237-45. PubMed ID: 21702063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
    Rulseh AM; Vymazal J
    J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas.
    Ellingson BM; Malkin MG; Rand SD; LaViolette PS; Connelly JM; Mueller WM; Schmainda KM
    J Neurooncol; 2011 Mar; 102(1):95-103. PubMed ID: 20798977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
    Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
    Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.
    Ellingson BM; Kim E; Woodworth DC; Marques H; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Int J Oncol; 2015 May; 46(5):1883-92. PubMed ID: 25672376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
    Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
    J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI and
    Wirsching HG; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P; Ochsenbein A; Tabatabai G; Weller M
    Clin Cancer Res; 2021 Jan; 27(1):179-188. PubMed ID: 32967939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.